

Asymmetric Synthesis of (+)-Hinokinin, (+)-Dihydrocubebin and Cubebin Dimethyl Ether, a New Lignan from *Phyllanthus niruri*

Dieter Enders and Mile Milovanović

Institut für Organische Chemie, RWTH Aachen University, Landoltweg 1, 52074 Aachen, Germany

Reprint requests to Prof. Dr. Dieter Enders. Fax: +49 241 809 2127. E-mail: enders@rwth-aachen.de

Z. Naturforsch. **2007**, 62b, 117–120; received August 23, 2006

The asymmetric synthesis of the new lignan cubebin dimethyl ether was accomplished in eight steps with an overall yield of 40%. In addition, the known lignans (+)-hinokinin and (+)-dihydrocubebin were synthesized by this route. Our approach involves the highly diastereoselective and enantioselective ($de \geq 98\%$, $ee \geq 98\%$) construction of a *trans*-substituted 2,3-dibenzylbutyrolactone through an asymmetric Michael addition of an enantiopure lithiated aminonitrile to 5*H*-furan-2-one.


Key words: Lignans, Nucleophilic Acylation, α -Aminonitrile, Michael Addition, Asymmetric Synthesis

Introduction

Cubebin dimethyl ether (**1**) is a new lignan which was recently isolated from cell suspension cultures of *Phyllanthus niruri* (*euphorbiaceae*) [1]. This plant is well-known in folk medicine as a remedy against different diseases like jaundice, asthma and bronchial infections [2]. Other lignans which were isolated from this plant also exhibited biological activities. Phyllanthin and hypophyllanthin show a moderately inhibitive effect on Gram-positive and Gram-negative bacteria and *anti*-oxidant activities [3]. (–)-*trans*-2-(3,4-Dimethoxybenzyl)-3-(3',4'-methylenedioxybenzyl)butyrolactone, also isolated from *Bursera schlehtendalii* [4], showed *anti*-tumor activities and nirtetralin and niranthin are known for their *anti*-human hepatitis B virus activity [5].

The structure of cubebin dimethyl ether (**1**) was assigned on the basis of mass spectrometric combined with ^1H and ^{13}C NMR data and supported by a H, H-COSY, HMQC, and HMBC NMR-spectroscopic analysis. The researchers who isolated this lignan assume the (8*S*,8'*S*) *trans*-configuration due to the biogenesis of cubebin dimethyl ether [1]. Up to now exists only one report on the synthesis of (8*R*,8'*R*)-cubebin dimethyl ether, starting from (–)-dihydrocubebin lignan and converting it in (8*R*,8'*R*)-cubebin dimethyl ether [6].

We now wish to report the first asymmetric synthesis of cubebin dimethyl ether (**1**) employing our asymmetric nucleophilic acylation methodology based on




Cubebin dimethyl ether (**1**)

lithiated α -aminonitriles [7a–h]. We first synthesized the enantiopure *trans*-configured 2,3-disubstituted γ -butyrolactone **6** [7i–j], which can be easily transformed to (+)-hinokinin (**8**), (+)-dihydrocubebin (**9**) and (8*S*,8'*S*)-cubebin dimethyl ether (**1**) in diastereo- and enantiomerically pure form. Needless to say that employing the enantiomer of the auxiliary amine **2** should give rise to the (8*R*,8'*R*) enantiomer of **1**.

Results and Discussion

As depicted in Scheme 1, the α -aminonitrile (8*S*,8'*S*)-**3** was obtained from the enantiomerically pure secondary amine (8*S*)-**2**, piperonal and potassium cyanide in HOAc/methanol [7k]. The aminonitrile was isolated in 81% yield as a mixture of α -epimers. Deprotonation of **3** with LDA in THF and reaction with 5*H*-furan-2-one at -78°C afforded the Michael adduct (8*S*,8'*S*)-**4** in high yield (79%) and diastereoselectivity ($de \geq 88\%$, after chromatography $de \geq 98\%$).

The second stereogenic centre of the natural compound was introduced by subsequent metalation of



Scheme 1. Reagents and conditions: (a) piperonal, MeOH, CH₃CO₂H, KCN; (b) 1. LDA, THF, –78 °C, 90 min; 2. 5H-furan-2-one, –78 °C; (c) 1. 1.2 eq. *t*-BuLi, THF, –78 °C, 90 min; 2. ArCH₂Br, –90 to 0 °C; (d) AgNO₃, H₂O, THF, 25 °C; (e) NaBH₄, MeOH/CH₂Cl₂; (f) H₂, Pd/C, HClO₄, MeOH, 4 atm, rt; (g) LiAlH₄, THF; (h) NaH (2.2 eq.), THF, MeI (8 eq.), 3 h.

^a After chromatography, determined by ¹H and ¹³C NMR. ^b Determined by ¹H NMR-shift reagent (Pirkle alcohol) [8].

the Michael adduct **4** with 1.2 equivalents of *t*-BuLi in THF at –100 °C and trapping of the enolate with 3,4-methylenedioxybenzyl bromide at this temperature. The resulting aminonitrile (*S,S,R,R,S*)-**5** was obtained in quantitative yield and high diastereomeric purity (*de* ≥ 98%). The silver nitrate mediated cleavage of the auxiliary provided the enantiopure *trans*-2,3-disubstituted γ -butyrolactone (*S,S*)-**6** with excellent asymmetric induction (*de* ≥ 98%, *ee* ≥ 98%) [7g–i]. First the reduction of the ketone **6** with sodium borohydride in methanol quantitatively gave the corresponding alcohol **7** as an epimeric mixture. The second step, catalytic hydrogenolysis with Pd/C at 4 atm, furnished (+)-hinokinin (**8**) in very good yield (88%) and excellent stereoisomeric purity *de* ≥ 98%, [α]_D²² = +33.0 (*c* = 1.6, CHCl₃) (lit. [9]: [α]_D²⁴ = +32.8 (*c* = 1.88, CHCl₃)). The subsequent reduction step with lithium aluminium hydride opened the butyrolactone ring and afforded the known lignan (+)-dihydrocubebin (**9**) in excellent yield (90%) with an optical rotation of [α]_D²² = +34.0 (*c* = 0.1, CHCl₃) in accordance

with the literature (lit. [10]: [α]_D²⁰ = –32.4 (*c* = 3.3, CHCl₃)). Finally, deprotonation of (+)-dihydrocubebin with NaH (2.2 eq.) and methylation with MeI (8 equiv.) provided the title cubebin dimethyl ether (**1**) in 98% yield. The spectroscopic data (NMR, IR, MS) were in accordance with the literature, but the optical rotations of (*S,S*)-**1** differed [α]_D²² = –3.1 (*c* = 0.1, CHCl₃) from those given for (*R,R*)-**1** (lit. [6]: [α]_D = –7.7°).

Conclusion

In conclusion, we have reported the first asymmetric synthesis of the new lignan cubebin dimethyl ether isolated from *Phyllanthus niruri* Linn. (*euphorbiaceae*) based on our conjugate asymmetric nucleophilic acylation methodology.

Experimental Section

All products were characterized by comparison of their spectroscopic data with those of the listed literature. All moisture-sensitive reactions were carried out by using stan-

dard Schlenk techniques. The chiral auxiliary (*S,S*)-**2** was prepared according to the literature procedure [7b]. Optical rotation values were measured on a Perkin-Elmer P241 polarimeter; solvents used were of Merck UVASOL quality. Microanalyses were obtained with a Heraeus CHN-O-RAPID or Vario EL element analyzer. Mass spectra were acquired on a Varian MAT 212 (EI, 70 eV, 1 mA) or Finnigan MAT SSQ 7000 (CI 100 eV) spectrometer. High resolution mass spectra were recorded on a Finnigan MAT 95 spectrometer. IR spectra were recorded on a Perkin-Elmer FT/IR 1760. ¹H NMR (300 and 400 MHz) and ¹³C NMR (75 and 100 MHz) spectra were recorded on Gemini 300 or Varian Inova 400 spectrometers with CDCl₃ as a solvent and TMS as an internal standard.

Compounds **3**, **4**, **5**, and **6** were prepared following the same procedure and experimental conditions as described previously [7k, 7g, 7i].

(+)-*Hinokinin* (**8**)

To a solution of ketone **6** (354 mg, 0.96 mmol) in CH₂Cl₂ (30 mL) was added NaBH₄ (0.12 g, 3.04 mmol) and MeOH (15 mL). After 2 h the reaction mixture was diluted with CH₂Cl₂ (30 mL) and water (10 mL). The aqueous phase was extracted three times with CH₂Cl₂ (15 mL). The combined organic layers were dried over MgSO₄ and evaporated in vacuum. The crude product was directly used for the next step. The epimeric mixture of alcohol **7** (356 mg, 0.96 mmol) was dissolved in dry ethanol (60 mL) and two drops of aqueous HClO₄ were added. The mixture was hydrogenated using Pd/C (60 mg) as a catalyst at 4 atm H₂ pressure. After 48 h, the solution was neutralized with Na₂CO₃ and the catalyst was filtered off. The solvent was evaporated in vacuum and the crude product was purified by column chromatography (Et₂O : pentane = 1 : 1) to give 299 mg (88 %) of (+)-hinokinin (**8**) as a colourless syrup. – IR (CHCl₃): ν = 2903 (s), 2362 (m), 1768 (s, C=O), 1492 (s), 1443 (s), 1247 (s), 1191 (s), 1038 (s), 928 (s), 811 (m), 756 (m), 668 (m). – ¹H NMR (400 MHz, CDCl₃): δ = 2.41–2.62 (m, 4H, OCH₂CHCH₂, OCH₂CHCH₂, OCCHCH₂), 2.84 (dd, *J* = 14.0, 7.1 Hz, 1H, OCCHCHH), 2.98 (dd, *J* = 14.0, 4.9 Hz, 1H, OCCHCHH), 3.85 (dd, *J* = 9.0, 7.4 Hz, 1H, OCHHCH), 4.12 (dd, *J* = 9.0, 7.1 Hz, 1H, OCHHCH), 5.93 (s, 4H, 2 × OCH₂O), 6.46 (m, 2H, arom. CH), 6.60 (dd, *J* = 7.9, 1.6 Hz, 1H, arom. CH), 6.62 (d, *J* = 1.6 Hz, 1H, arom. CH), 6.69 (d, *J* = 8.2 Hz, 1H, arom. CH), 6.73 (d, *J* = 7.7 Hz, 1H, arom. CH) ppm. – ¹³C NMR (100 MHz, CDCl₃): δ = 34.76 (CH₂CHCO), 38.29 (CH₂CHCH₂O), 41.22 (CH₂CHCH₂), 46.40 (CH₂CHCO), 71.02 (CHCH₂O), 100.86 (OCH₂O), 108.10, 108.17, 108.64, 109.26, 121.35, 122.03 (arom. CH), 131.13, 131.41, 146.12, 146.24, 147.63, 147.66 (arom. C), 178.14 (CO) ppm. – MS (EI, 70 eV): *m/z* (%) = 355 (15) [M+1]⁺, 354 (67) M⁺, 219 (6), 217 (16), 172 (6), 161 (8), 160 (7), 135 (33), 134 (100), 130 (7),

105 (5), 77 (15). – C₂₀H₁₈O₆ (354.35): calcd. C 67.79, H 5.12; found C 68.05, H 5.23.

(+)-*Dihydrocubebin* (**9**)

To a suspension of LiAlH₄ (28 mg, 0.74 mmol) in dry THF (5 mL) at 0 °C under Ar, a solution of (+)-hinokinin (130 mg, 0.37 mmol) in dry THF (5 mL) was slowly added *via* syringe. The reaction mixture was stirred at 0 °C for 0.5 h and then at r. t. for further 0.5 h. After addition of EtOAc (20 mL) the reaction mixture was quenched with saturated aqueous NH₄Cl (10 mL) and water (5 mL). The water phase was separated and extracted three times with EtOAc (10 mL). The combined organic layers were dried over MgSO₄ and evaporated in vacuum. The crude product was purified by column chromatography (Et₂O) to give (+)-dihydrocubebin (**9**) (119 mg, 90 %) as colourless cubes. – M.p. 102 °C (lit. [11]: 103–104 °C). – IR (KBr): ν = 3852 (s), 3742 (s), 3681 (m), 3430 (m), 3337 (m), 2361 (s), 2339 (s), 1700 (s), 1650 (s), 1505 (s), 1246 (s), 1036 (s), 669 (m). – ¹H NMR (300 MHz, CDCl₃): δ = 1.83 (m, 2H, 2 × CH₂CHCH₂), 2.60 (dd, *J* = 13.6, 5.6 Hz, 2H, 2 × CCHH), 2.73 (dd, *J* = 13.6, 8.6 Hz, 2H, 2 × CCHH), 3.48 (dd, *J* = 11.1, 3.9 Hz, 2H, 2 × CHHOH), 3.76 (d, *J* = 11.1 Hz, 2H, 2 × CHHOH), 3.83 (s, 2H, 2 × CH₂OH), 5.90 (s, 4H, 2 × OCH₂O), 6.59 (d, *J* = 7.9 Hz, 2H, arom. CH), 6.63 (s, 2H, arom. CH), 6.70 (d, *J* = 7.9 Hz, 2H, arom. CH) ppm. – ¹³C NMR (75 MHz, CDCl₃): δ = 35.89 (CCH₂), 44.26 (CH₂CHCH₂), 60.02 (CH₂OH), 100.77 (OCH₂O), 108.09, 109.33, 121.86 (arom. CH), 134.36, 145.69, 147.55 (arom. C) ppm. – MS (EI, 70 eV): *m/z* (%) = 359 (7) [M+1]⁺, 358 (38) M⁺, 340 (14), 203 (22), 191 (10), 187 (14), 174 (5), 172 (8), 160 (6), 136 (34), 135 (100), 130 (5), 77 (10). – C₂₀H₂₂O₆ (358.39): calcd. C 67.03, H 6.19; found C 67.27, H 6.12.

Cubebin dimethyl ether (**1**)

To a stirred solution of (+)-dihydrocubebin (**9**) (60 mg, 0.20 mmol) in dry THF (5 mL) methyl iodide (123 mg, 0.86 mmol), sodium hydride (370 mg, 9.20 mmol, 60 % dispersion in oil) and a second portion of methyl iodide (68 mg, 0.48 mmol) were added. After 2.5 h at r. t., the mixture was cooled to 0 °C and methanol (5 mL) was added. Concentration under reduced pressure and flash chromatography of the crude compound (Et₂O : pentane = 1 : 3) afforded 76 mg (98 %) of cubebin dimethyl ether (**1**) as a colourless oil. – IR (CHCl₃): ν = 2889 (s), 2356 (s), 1493 (s), 1477 (s), 1246 (s), 1195 (m), 1111 (s), 1040 (s), 933 (m), 866 (s), 808 (m), 758 (s). – ¹H NMR (400 MHz, CDCl₃): δ = 2.01 (m, 2H, 2 × CH₂CHCH₂), 2.56 (dd, *J* = 13.7, 8.2 Hz, 2H, 2 × CCHH), 2.65 (dd, *J* = 13.7, 6.0 Hz, 2H, 2 × CCHH), 3.28 (s, 6H, 2 × CH₃O), 3.28 (dd, *J* = 9.9, 4.9 Hz, 4H, 2 × CH₃OCH₂), 5.91 (s, 4H, 2 × OCH₂O), 6.56 (dd, *J* = 7.9, 1.6 Hz, 4H, arom. CH), 6.70 (d, *J* = 7.9 Hz, 2H, arom. CH) ppm. – ¹³C NMR (100 MHz, CDCl₃): δ = 34.81 (CCH₂), 40.89

(CH₂CHCH₂), 58.60 (CH₃O), 72.39 (CH₃OCH₂), 100.54 (OCH₂O), 107.76, 109.25, 121.70 (arom. CH), 134.67, 145.31, 147.22 (arom. C) ppm. – MS (EI, 70 eV): *m/z* (%) = 387 (19) [M+1]⁺, 386 (78) M⁺, 355 (12), 354 (54), 322 (19), 219 (8), 217 (14), 206 (5), 204 (5), 188 (5), 186 (43), 185 (8), 173 (15). – HRMS: calcd. 386.172938; found 386.172940.

Acknowledgements

This work was supported by the Fonds der Chemischen Industrie. We thank BASF AG, Bayer AG and the former Boehringer Mannheim GmbH for the donation of chemicals.

- [1] Elfahmi, S. Batterman, A. Koulman, T. Hackl, R. Bos, O. Kayser, H. J. Woerdenbag, W. J. Quax, *J. Nat. Prod.* **2006**, 69, 55 – 58.
- [2] L. R. Row, C. Srinivasulu, M. Smith, G. S. R. Subba Rao, *Tetrahedron Lett.* **1964**, 5, 1557 – 1567.
- [3] V. D. Nguyen, H. N. Luu, D. C. Nguyen, *Tap Chi Duoc Hoc* **2003**, 12 – 14.
- [4] P. Satyanarayana, S. Venkateswarlu, *Tetrahedron* **1991**, 47, 8931 – 8940.
- [5] R.-L. Huang, Y.-L. Huang, J.-C. Ou, C.-C. Chen, F.-L. Hsu, C. Chang, *Phytotherapy Res.* **2003**, 17, 449 – 453.
- [6] A. S. R. Anjaneyulu, P. A. Ramaiah, L. R. Row, R. Venkateswarlu, A. Pelter, R. S. Ward, *Tetrahedron* **1981**, 37, 3641 – 3652.
- [7] For a review on α -aminonitrile chemistry, see: a) D. Enders, J. P. Shilvock, *Chem. Soc. Rev.* **2000**, 29, 359 – 373; b) D. Enders, H. Lotter, N. Maigrot, J. P. Mazaleyra, Z. Welvert, *Nouv. J. Chim.* **1984**, 8, 747 – 750; c) D. Enders, P. Gerdes, H. Kipphardt, *Angew. Chem.* **1990**, 102, 226 – 228; *Angew. Chem. Int. Ed. Engl.* **1990**, 29, 179 – 181; d) G. Raabe, E. Zobel, J. Fleischhauer, P. Gerdes, D. Mannes, E. Müller, D. Enders, *Z. Naturforsch.* **1991**, 46a, 275 – 288; e) D. Enders, D. Mannes, G. Raabe, *Synlett* **1992**, 837 – 839; f) D. Enders, J. Kirchhoff, D. Mannes, G. Raabe, *Synthesis* **1995**, 659 – 666; g) D. Enders, J. Kirchhoff, V. Lausberg, *Liebigs Ann.* **1996**, 1361 – 1366; h) D. Enders, J. Kirchhoff, P. Gerdes, D. Mannes, G. Raabe, J. Runsink, G. Boche, M. Marsch, H. Ahlbrecht, H. Sommer, *Eur. J. Org. Chem.* **1998**, 63 – 72. For previous lignan syntheses of our group, see: i) D. Enders, V. Lausberg, G. Del Signore, O. M. Berner, *Synthesis* **2002**, 515 – 522; j) D. Enders, G. Del Signore, O. M. Berner, *Chirality* **2003**, 15, 510 – 513; k) D. Enders, M. Milovanović, E. Voloshina, G. Raabe, J. Fleischhauer, *Eur. J. Org. Chem.* **2005**, 1984 – 1990.
- [8] W. H. Pirkle, D. L. Sikkenga, M. S. Pavlin, *J. Org. Chem.* **1977**, 42, 384 – 387.
- [9] T. Morimoto, H. Nagai, K. Achiwa, *Synth. Comm.* **2005**, 35, 857 – 865.
- [10] J. E. Batterbee, R. S. Burden, L. Crombie, D. A. Whiting, *J. Chem. Soc. (C)* **1969**, 2470 – 2477.
- [11] G. Bruchhausen, *Chem. Ber.* **1939**, 72, 830 – 836.